Abstract
BACKGROUND: Airway pressure release ventilation (APRV) is a commonly used mode of ventilation designed to increase mean airway pressure and thus oxygenation. Different strategies for clinical management have been described in the literature but are largely based on physiologic concepts, animal data, and small clinical trials. The purpose of this study was to determine how APRV is currently managed by surveying practicing respiratory therapists with experience using APRV.
METHODS: A 15-item survey was developed by the authors and posted on the AARConnect online media platform in January 2016 after being declared exempt by our institution's institutional review board. Survey questions were derived from a literature review of recommended APRV settings. Responses were limited to one per institution.
RESULTS: The survey was completed by 60 respondents who used APRV. Of the 4 key initial APRV settings (P high, P low, T high, and T low), there was good agreement among survey responders and published guidelines for setting initial T high (4–6 s) and initial P low (0 cm H2O). There was some disagreement regarding initial P high, with 48% of responders matching P high to conventional ventilation plateau pressures but another 31% using conventional ventilation mean airway pressure plus 2–5 cm H2O. The most disagreement was with the T low setting, with only 47% of survey responders agreeing with published guidelines about using the expiratory flow signal to set T low. There was good agreement among survey responders and published guidelines for what changes to make when gas exchange was outside of the targeted range. A substantial number of respondents accepted P high and APRV release volumes that may exceed lung-protective limits.
CONCLUSIONS: There is only limited consensus among practitioners for initial APRV settings, probably reflecting the paucity of good clinical outcome data and confusion surrounding the physiology of this mode.
Introduction
Airway pressure release ventilation (APRV) is a mode of mechanical ventilation originally described as CPAP with an intermittent release phase configured with inspiratory time greater than expiratory time. It can also be described as pressure control intermittent mandatory ventilation with inverse ratio of inspiratory time to expiratory time (I:E) and unrestricted spontaneous breathing.1,2 Conceptually, APRV is a form of open lung ventilation designed to increase mean airway pressure without increasing set PEEP, set driving pressure, or tidal volume in patients with acute lung injury, ARDS, postoperative atelectasis, or increased chest wall elastance. To date, some reports,2–8 but not all,9 have found conventional mechanical ventilation and APRV to have similar safety profiles. When compared with conventional strategies, small randomized trials and a larger propensity-matched study indicate that APRV may improve oxygenation (as measured by PaO2/FIO2) but appears to have no effect on mortality or other patient-oriented outcomes.3–8 Despite the lack of high-level evidence that APRV improves important patient oriented outcomes, APRV is used in many ICUs around the world.3
Although APRV settings are similar in concept to those used during conventional mechanical ventilation, there are important technical differences. The 4 key APRV settings are: (1) lung inflation pressure or P high; (2) lung inflation time or T high; (3) lung deflation pressure or P low; and (4) lung deflation time or T low. Importantly, APRV is usually set with a long T high/short T low to create an inverse I:E. Also, during T high, spontaneous breathing (with or without pressure support) can occur.
Specific management strategies to set these 4 parameters have been described in the literature.10,11 However, these strategies are largely based on theoretical considerations, animal studies, and small clinical trials rather than large randomized trials. Moreover, how APRV is actually being managed at the bedside is generally unknown. The purpose of this study was to examine APRV usage and clinical management strategies through the use of a survey instrument administered to practicing respiratory therapists.
QUICK LOOK
Current knowledge
Airway pressure release ventilation (APRV) is a commonly used mode of ventilation designed to increase mean airway pressure and thus oxygenation. Different strategies for clinical management have been described in the literature but are largely based on physiologic concepts, animal data, and small observational trials. How APRV is being managed at the bedside in different institutions is largely unknown.
What this paper contributes to our knowledge
This survey highlights the lack of consensus among practitioners regarding initial APRV settings, probably reflecting the paucity of good clinical outcome data and confusion surrounding the physiology of this mode. In addition, some respondents reported APRV settings outside of current lung-protective standards, reflecting an underappreciation of the potential harm that can result from APRV.
Methods
A survey instrument relating to APRV clinical management strategies was developed by the authors and declared exempt by our institution's institutional review board. The survey was developed after reviewing the published literature and included clinical management choices included in recommendations from Habashi10 and Modrykamien et al.11 The initial survey instrument was tested on 144 personal contacts to refine the questions and clarify ambiguities. After receiving approval from the AARC Board of Directors, the final survey was posted on the AARConnect listserv on January 4, 2016. Reminder posts were posted weekly for 4 weeks. Participants were limited to one per institution to eliminate institutional bias.
The survey consisted of 15 questions (see the supplementary materials at http://www.rcjournal.com), which related to hospital demographics, mechanical ventilation protocol use, rescue modes used, and APRV management strategies. CIs were calculated using the modified Wald method to underscore that the results lack precision.12
Results
There were a total of 60 responses from hospitals that used APRV. Respondent and hospital demographic data are summarized in Table 1. In these hospitals, proning capabilities existed in 71%, high-frequency oscillators were available in 34%, and extracorporeal membrane oxygenation was available in 49%. Nevertheless, 74% of these hospitals used APRV as the initial rescue strategy for patients failing conventional ventilation. APRV was managed via institutional protocol in 48% of centers, and 44% used pressure support during APRV.
Respondents' initial approaches for APRV management are summarized in Table 2. To put these into perspective, the 4 key APRV settings (P high, T high, P low, T low) in our survey response are compared with 2 commonly recommended published strategies from the Cleveland Clinic11 and the University of Maryland Shock Trauma Unit10 in Table 3. For P high, both published strategies recommend matching the plateau pressure (Pplat) from the baseline conventional ventilation settings, but only 48% of our survey responders agreed with that. Another 31% used an initial P high 2–5 cm H2O above the mean pressure on baseline conventional mechanical ventilation. There was more agreement with P low. Both published strategies recommend 0 cm H2O, and 78% of the survey responders agreed. There was also substantial agreement with initial settings for T high. Both published strategies recommended 4 or 4–6 s, and 65% of the survey responders agreed. Of note is that 20% of the survey responders felt that minute ventilation and I:E should also be taken into account for setting T high. Substantial variability in our results was seen in the approach to T low. Both published strategies recommend setting T low using the expiratory flow signal to ensure that substantial auto-PEEP is generated, one recommending setting T low to end when 40% of the peak expiratory flow is reached and the other recommending setting T low to end when 50–75% of the peak expiratory flow is reached. In contrast, only 51% of our survey responders used expiratory flow criteria to set T low (37% using 56–75% of peak expiratory flow), whereas 39% used a fixed T low (0.2–0.8 s) when using APRV.
For changes made when gas exchange is below targets for oxygenation or ventilation, our survey responders were remarkably consistent and in general agreement with published recommendations.10,11 To improve ventilation, P high would be increased to increase tidal volume by 98% of our survey responders, and T high would be shortened to increase breathing rate by 90% of our survey responders. Interestingly, 51% of our survey responders would also add pressure support to improve ventilation. To improve oxygenation, again P high would be increased by 94% of our survey responders, whereas increasing the I:E (increase T high/decrease T low) would be done by 78% of our survey responders. One interesting departure from published recommendations10,11is that 52% of our survey responders would increase P low to improve oxygenation.
Our survey responders did not always seem concerned about limiting maximal and tidal lung stretch to minimize ventilator-induced lung injury. Thirty-six percent of our survey responders would accept APRV P high settings > 35 cm H2O, and 44% would accept APRV release volumes > 8 mL/kg (ideal body weight).
Discussion
Our survey results showed that APRV was the first choice for most respondents for patients failing conventional mechanical ventilation. However, there was only modest consensus for initial settings used during APRV among those surveyed. In addition, respondents' initial management strategies often deviated from published guidelines.10,11
APRV offers some interesting physiologic features that may have utility in the management of patients with acute respiratory failure. However, APRV is not an on-off switch; it requires manipulation of 4 key variables. At the present time, the optimal way to configure these variables for various clinical scenarios is largely based on physiologic concepts, small trials, and clinical experience rather than on results from large randomized trials. As a consequence, interpreting trials and making recommendations about APRV is problematic.
The most marked variability in survey responses and deviation from APRV published guidelines was in the choice of T low. Both published guidelines10,11 recommend using expiratory flow analysis to ensure that the set T low creates significant auto-PEEP. However, 39% of our respondents used an arbitrary set time instead. The use of auto-PEEP rather than set PEEP to maintain alveolar recruitment is controversial. Whereas set PEEP distributes to all alveolar units, auto-PEEP is most prominent in alveolar units with slow emptying (high-compliance/high-resistance units) and is least prominent in alveolar units with fast emptying (low-compliance/low-resistance units).13 Conceptually, this would seem opposite of the clinical goals for PEEP in patients with alveolar inflammation, flooding, or collapse. Clinical trials are clearly needed to sort this out.
A high percentage of respondents appeared to expose patients to potentially harmful end-inspiratory and tidal lung distention. Current standards for lung-protective conventional ventilation are to limit end-inspiratory Pplat to < 30 cm H2O and tidal volume to < 8 mL/kg.14,15 The 2 published APRV guidelines10,11 do not specifically address these parameters. Instead, the only recommendation is to limit P high to < 30–35 cm H2O, a limit that 36% of our respondents were willing to exceed. Importantly, limiting P high is not the same as limiting Pplat, and the harm from exceeding P high may be worse than that from exceeding Pplat. Specifically, Pplat, by definition, is measured in the absence of patient effort and under no-flow conditions. In the setting of nearly normal chest wall mechanics, Pplat is an approximation of the end-inspiratory transpulmonary pressure, the actual stretching pressure on lung tissue. In contrast, APRV encourages patient effort and patient-generated flow (often augmented with pressure support) that can take the end-inspiratory trans-pulmonary pressure well above the set P high. Targeting a P high of < 30–35 cm H2O may thus underestimate the risk of overdistention during APRV. We believe that this important point is often underappreciated by clinicians managing patients receiving APRV.
The published APRV guidelines10,11 pay little attention to monitoring tidal volumes, a parameter increasingly appreciated as an independent risk factor for ventilator-induced lung injury.14,15 Reasonable data support generally limiting tidal volumes to < 8 mL/kg (ideal body weight).14,15 However, 44% of our respondents were willing to exceed this value for the release volume. Importantly, the effective tidal distention of the lung during APRV is not only the release volume but also whatever volume is added during spontaneous breathing (with or without pressure support).
Although we did not specifically address driving pressure in our survey, this is another parameter that could reflect regional tidal alveolar overdistention during APRV.14 The driving pressure during conventional ventilation is the Pplat minus the measured PEEP. However, this is not equivalent to P high minus P low in APRV. This is because of the potential differences in set P high versus a true Pplat noted above and because the actual total PEEP in the lungs is the set P low plus the unevenly distributed intentional auto-PEEP. Thus, determining a driving pressure during APRV is clearly problematic and in need of considerable further study before being incorporated into APRV management algorithms.
Our survey has important limitations, and thus results should be interpreted cautiously. The sample size of 60 is small, and the sampling method used carries self-selection bias because only members of the AARConnect Adult Acute Care Section were surveyed. The small sample size also prevented any analysis of regional differences in clinical practice. However, respondents were probably well-versed in APRV, had a special interest in APRV, and were motivated to contribute to our understanding of APRV. Our survey results therefore would seem to provide exploratory data opening a window into the clinical management of APRV.
Another important limitation of our study is simply the nature of a voluntary survey. Questions must be short and few in number to obtain a reasonable response level. Details of the clinical scenario surrounding a question are thus limited, and nuances cannot be explored. Finally, the terminology surrounding APRV is confusing, a situation worsened by manufacturers insisting on proprietary names and non-standardized ways to display settings and monitors.
Conclusions
There is only limited consensus among practitioners for initial APRV settings, probably reflecting the paucity of good clinical outcome data and confusion surrounding the physiology of this mode. In addition, there may be an underappreciation by some practitioners of the potential harm that can result from APRV.
Footnotes
- Correspondence: Neil R MacIntyre MD FAARC, Duke University Medical Center, Respiratory Care Services, PO Box 3911, 2301 Erwin Road, Durham NC 27710. E-mail: neil.macintyre{at}duke.edu.
Supplementary material related to this paper is available at http://www.rcjournal.com.
This work was supported by departmental funding. Dr MacIntyre discloses relationships with InspiRx Pharmaceuticals, Breathe Technologies, Ventec Life Support, Alana Healthcare, and Pulmonx. Mr Davies discloses a relationship with ResMed. Mr Gentile discloses relationships with Medical Dynamics and Draeger. Mr Miller has no conflicts to disclose.
- Copyright © 2017 by Daedalus Enterprises